The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis.

ABSTRACT:

Objectives

Dasatinib 100 mg daily and nilotinib 600/800 mg daily have been compared to imatinib as first line treatments for CML in two recent randomised studies. However, no head to head evidence exists of the relative efficacy of dasatinib and nilotinib.

Methods

We conducted a systematic literature review and used the data extracted to perform an indirect comparison meta-analysis of the three interventions.

Results

Data from eight clinical studies (3,520 individuals) were included, all of which were of good quality (low risk of bias). At six months, the odds of complete cytogenetic response (CCyR) for dasatinib and nilotinib were approximately three times those for imatinib (range 2.77 to 3.06, all values not significant). At twelve months datatinib and nilotinib we

SUBMITTER: Mealing S 

PROVIDER: S-EPMC3585848 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature